Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yao, Wei ^a   Zhang, Ji Chun ^a   Ishima, Tamaki ^a   Dong, Chao ^a   Yang, Chun ^a   Ren, Qian ^a   Ma, Min ^a   Han, Mei ^a   Wu, Jin ^a   Suganuma, Hiroyuki ^b   Ushida, Yusuke ^b   Yamamoto, Masayuki ^c   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KAGOME CO   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCORAPHANIN; GLUCOSINOLATE; IMIDOESTER; KEAP1 PROTEIN, MOUSE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NRF2;

ANIMAL; C57BL MOUSE; DEPRESSION; DIET; DISEASE MODEL; GENETICS; HIPPOCAMPUS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; DEPRESSION; DIET; DISEASE MODELS, ANIMAL; GLUCOSINOLATES; HIPPOCAMPUS; IMIDOESTERS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; PREFRONTAL CORTEX; SIGNAL TRANSDUCTION;

EID: 84979935392     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30659     Document Type: Article

References (76)

1. Whiteford, H. A. et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382, 1575-1586 (2013).
2. Walker, E. R., McGee, R. E., Druss, B. G. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72, 334-341 (2015).
3. Mukakami, K., Sasaki, S. Dietary intake and depressive symptoms: a systemic review of observational studies. Mol Nutr Food Res. 54, 471-488 (2010).
4. Bazinet, R. P., Layé, S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 15, 771-785 (2014).
5. Mello, A. H. et al. ?-3 and major depression: a review. Acta Neuropsychiatr 26, 178-185 (2014).
6. El-Behadli, A. F. et al. Maternal depression, stress and feeding styles: towards a framework for theory and research in child obesity. Br J Nutr 113, S55-S71 (2015).
7. Opie, A., O'Neil, R. S., Itsiopoulos, C., Jacka, F. N. The impact of whole-of-diet interventions on depression and anxiety: a systematic review of randomised controlled trials. Public Health Nutr 18, 2074-2093 (2015).
8. Lai, J. S. et al. A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. Am J Clin Nutr. 99, 181-197 (2014).
9. Liu, X., Yan, Y., Li, F., Zhang, D. Fruit and vegetable consumption and the risk of depression: A meta-analysis. Nutrition 32, 296-302 (2016).
10. Paus, T., Keshavan, M., Giedd, J. N. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 9, 947-957 (2008).
11. O'Connor, R. M., Cryan, J. F. Adolescent brain vulnerability and psychopathology through the generations: role of diet and dopamine. Biol Psychiatry 75, 4-6 (2014).
12. Dantzer, R. et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Rev Neurosci. 9, 46-57 (2008).
13. Hashimoto, K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev. 61, 105-123 (2009).
14. Miller, A. H., Maletic, V., Raison, C. L. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65, 732-741 (2009).
15. Raison, C. L., Lowry, C. A., Rook, G. A. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry 67, 1211-1224 (2010).
16. Hashimoto, K. Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci. 16, 7796-7801 (2015).
17. Zhang, J. C., Yao, W., Hashimoto, K. Brain-derived neurotrophic factor (BDNF)-TrkB signaling in inflammation-related depression and potential therapeutic targets. Curr Neuropharmacol doi: 10.2174/1570159X14666160119094646 (2016).
18. Dowlati, Y. et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 67, 446-457 (2010).
19. Young, J. J., Bruno, D., Pomara, N. A review of the relationship between pro-inflammatory cytokines and major depressive disorder. J Affect Disord 169, 15-20 (2014).
20. Haapakoski, R. et al. Cumulative meta-analysis of interleukins 6 and 1?, tumour necrosis factor ? and C-reactive protein in patients with major depressive disorder. Brain Behav Immun 49, 206-215 (2015).
21. Dean, B., Tawadros, N., Scarr, E., Gibbons, A. S. Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord 120, 245-248 (2010).
22. Shelton, R. C. et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 16, 751-762 (2011).
23. Ma, Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53, 401-426 (2013).
24. Kobayashi, E., Suzuki, T., Yamamoto, M. Roles nrf2 plays in myeloid cells and related disorders. Oxid Med Cell Longev 2013, 529219 (2013).
25. Suzuki, T., Motohashi, H., Yamamoto, M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci. 34, 340-346 (2013).
26. Suzuki, T., Yamamoto, M. Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med. 88, 93-100 (2015).
27. O'Connell, M. A., Hayes, J. D. The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem Soc Trans 43, 687-689 (2015).
28. Wardyn, J. D., Ponsford, A. H., Sanderson, C. M. Dissecting molecular cross-talk between Nrf2 and NF-? B response pathways. Biochem Soc Trans 43, 621-626 (2015).
29. Zhang, Y., Talalay, P., Cho, C. G., Posner, G. H. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 89, 2399-2403 (1992).
30. Fahey, J. W., Zhang, Y., Talalay, P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 94, 10367-10372 (1997).
31. Kensler, T. W. et al. Keap1-Nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem. 329, 163-177 (2013).
32. Juge, N., Mithen, R. F., Traka, M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 64, 1105-1127 (2007).
33. Kwak, M. K., Kensler, T. W. Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol 244, 66-76 (2010).
34. Fahey, J. W. et al. Sulforaphane bioavailability from glucoraphanin-rich broccoli: control by active endogenous myrosinase. PLos One 10, e0140963 (2015).
35. Nestler, E. J. et al. Neurobiology of depression. Neuron 34, 13-25 (2002).
36. Hashimoto, K., Shimizu, E., Iyo, M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev. 45, 104-114 (2004).
37. Duman, R. S., Monteggia, L. M. A neutrotrophic model for stress-related mood disorders. Biol Psychiatry 59, 1116-1127 (2006).
38. Hashimoto, K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64, 341-357 (2010).
39. Hashimoto, K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 100, 15-29 (2013).
40. Castrén, E. Neurotrophins and psychiatric disorders. Handb Exp Pharmacol 220, 461-479 (2014).
41. Björkholm, C., Monteggia, L. M. BDNF-a key transducer of antidepressant effects. Neuropharmacology 102, 72-79 (2015).
42. Berton, O. et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311, 864-868 (2006).
43. Jang, S. W. et al. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 107, 2687-2692 (2010).
44. Ren, Q. et al. Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating deficits in mice after administration of methamphetamine. Pharmacol Biochem Behav 106, 124-127 (2013).
45. Ren, Q. et al. 7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology (Berl) 231, 159-166 (2014).
46. Ren, Q. et al. BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms. Transl Psychiatry 5, e666 (2015).
47. Zhang, J. C. et al. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 18, pii: pyu077 (2015).
48. Zhang, J. C. et al. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology 232, 4325-4335 (2015).
49. Cazorla, M. et al. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 121, 1846-1857 (2011).
50. Chen, H. et al. Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine. Psychopharmacology (Berl) 222, 37-45 (2012).
51. Shirai, Y., Fujita, Y., Hashimoto, K. Effects of the antioxidant sulforaphane on hyperlocomotion and prepulse inhibition deficits in mice after phencyclidine administration. Clin Psychopharmacol Neurosci 10, 97-98 (2012).
52. Shirai, Y. et al. Dietary intake of sulforaphane-rich broccoli sprout extracts during Juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PLos One 10, e0127244 (2015).
53. Muramatsu, H. et al. Nrf2 deficiency leads to behavioral, neurochemical and transcriptional changes in mice. Genes Cells 18, 899-908 (2013).
54. Black, C. N. et al. Oxidative stress, anti-oxidants and the cross-sectional and longitudinal association with depressive symptoms: results from the CARDIA study. Transl Psychiatry 6, e743 (2016).
55. Smaga, I. et al. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism. Pharmacol Rep. 67, 569-580 (2015).
56. Dwivedi, Y. et al. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosin kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60, 804-815 (2003).
57. Karege, F. et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res. 136, 29-37 (2005).
58. Yang, C. et al. Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol 18, pyu121 (2015).
59. Yang, C. et al. R-Ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5, e632 (2015).
60. Shirayama, Y. et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 22, 3251-3261 (2002).
61. Shirayama, Y. et al. Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol 25, 2449-2458 (2015).
62. Monteggia, L. M. et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA 101, 10827-10832 (2004).
63. Saarelainen, T. et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci. 23, 349-357 (2003).
64. Monteggia, L. M. et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry 61, 187-197 (2007).
65. Martín-de-Saavedra, M. D. et al. Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 38, 2010-2022 (2013).
66. Mendez-David, I. et al. Nrf2-signaling and BDNF: A new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression. Neurosci Lett. 597, 121-126 (2015).
67. Howren, M. B., Lamkin, D. M., Suls, J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 71, 171-186 (2009).
68. Strawbridge, R. et al. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur. Neuropsychopharmacol 25, 1532-1543 (2015).
69. Singh, K. et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA 111, 15550-15555 (2014).
70. Shiina, A. et al. An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia. Clin Psychopharmacol Neurosci. 13, 62-67 (2015).
71. Ishima, T. et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol 25, 505-511 (2015).
72. Itoh, K. et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236, 313-322 (1997).
73. Bennett, R. N. et al. Profiling glucosinolates, flavonoids, alkaloids, and other secondary metabolites in tissues of Azima tetracantha L. (Salvadoraceae). J Agric Food Chem. 52, 5856-5862 (2004).
74. West, L. G. et al. Glucoraphanin and 4-hydroxyglucobrassicin contents in seeds of 59 cultivars of broccoli, raab, kohlrabi, radish, cauliflower, brussels sprouts, kale, and cabbage. J Agric Food Chem. 52, 916-926 (2004).
75. Golden, S. A., Covington, H. E. 3rd., Berton, O., Russo, S. J. A standardized protocol for repeated social defeat stress in mice. Nat Protoc 6, 1183-1191 (2011).
76. Walsh, J. J. et al. Stress and CRF gate neural activation of BDNF in the mesolimbic reward pathway. Nat Neurosci. 17, 27-29 (2014).